Review Article

Intestinal Organoids as a Novel Complementary Model to Dissect Inflammatory Bowel Disease

L. Schulte, M. Hohwieler, M. Müller, and J. Klaus

Department of Internal Medicine 1, University Medical Centre Ulm, Ulm, Germany

Correspondence should be addressed to L. Schulte; 7strx@gmx.net

Received 28 November 2018; Accepted 4 February 2019; Published 19 March 2019

Guest Editor: Purushothama R.

Copyright © 2019 L. Schulte et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory bowel diseases (IBDs) include colitis ulcerosa and Crohn’s disease, besides the rare microscopic colitis. Both diseases show a long-lasting, relapsing-remitting, or even chronic active course with tremendous impact on quality of life. IBDs frequently cause disability, surgical interventions, and high costs; as in other autoimmune diseases, their prevalent occurrence at an early phase of life raises the burden on health care systems. Unfortunately, our understanding of the pathogenesis is still incomplete and treatment therefore largely focuses on suppressing the resulting excessive inflammation. One obstacle for deciphering the causative processes is the scarcity of models that parallel the development of the disease, since intestinal inflammation is mostly induced artificially; moreover, the intestinal epithelium, which strongly contributes to IBD pathogenesis, is difficult to assess.

Recently, the development of intestinal epithelial organoids has overcome many of those problems. Here, we give an overview on the current understanding of the pathogenesis of IBDs with reference to the limitations of previous well-established experimental models. We highlight the advantages and detriments of recent organoid-based experimental setups within the IBD field and suggest possible future applications.

1. Multifactorial Pathogenesis of Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBDs), mainly summarizing Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by chronic relapsing-remitting or continuously active inflammation of the bowel, sometimes accompanied by extraintestinal affections, including diseases of the liver, skin, joints, or eyes.

UC affects the colon with an exclusively mucosal inflammation that almost invariably involves the rectum and spreads continuously to the variable segments of the colon, causing ulcers and leading to bloody diarrhea, accompanied by abdominal pain and signs of systemic inflammation like fever. In severe UC, a septic disease and a colonic distension called toxic megacolon with imminent perforation can develop, with possibly fatal consequences. Long-term complication is first of all the increase in risk for colonic carcinoma [1] especially in patients with an affection proximal to the colon sigmoideum. Furthermore, primary sclerosing cholangitis is associated in about 10% of cases, causing cirrhosis of the liver and its complications.

CD, on the other hand, can affect any part of the gastrointestinal tract from oral cavity to perianal skin, with the distal ileum being the most commonly affected part of it. The disease afflicts the patient with pain and diarrhea. The inflammation in CD is transmural, giving rise to fistulas, abscesses, and strictures, which often lead to the need of surgical resection; affection of the small intestine also leads to malassimilation and malabsorption.

The highest prevalence of IBD is found in highly developed countries, where about 300/100,000 people are affected by each UC and CD [2], with a markedly increased risk for relatives of affected persons [3]. Given the young age of onset of 15–35 years, the associated disease-related reduction of the quality of life [4] and the high morbidity [5, 6], the impact on these young patients is massive. Adding the high direct and indirect costs of the IBD [7] makes them one of the five most expensive gastrointestinal diseases [7, 8]. The need for research on them is obvious.
The current pathogenetic model of IBD is based on an inappropriate response of the hosts' immune system to intestinal microbial factors, in part as the consequence of an ineffective barrier between luminal flora and subepithelial tissues and in part because of an imbalance in the immune reaction of the mucosal immune system [9, 10]. Antibiotics have been used to treat acute IBD flares for a long time, rising suspicion about a crucial role of bacteria in its pathogenesis. Already 20 years ago, it was shown that most mouse models for IBD did not develop intestinal inflammation in germ-free conditions [11–13], but even with currently highly detailed techniques of microbiome analyses, no specific pathogenetic organism could be identified [14] and in only one single mouse model a transmittable “colitogenic” flora could be shown; nonetheless, there are specific changes in the composition in the intestinal flora of IBD patients. Further, supporting the role of bacteria in pathogenesis, it was found that in IBD, in contrast to healthy controls, bacteria were able to penetrate the mucus layer [15], maybe in part because of a differing composition of the mucus [16]. Next, bacteria must trigger an immune reaction to cause the intestinal inflammation. Although studies showed increased mucosal permeability in IBD [17], associations with genes involved in mucosal integrity [18–20], an oligoclonal T cell population in the lamina propria [21] suggestive of an antigen-driven immune reaction, and more recently a disruption of the subepithelial band of lamina propria macrophages [22], mucosal adherence or penetration by bacteria could not be shown [15]. Instead, epithelial cells themselves are able to process and present antigens [23], and the inflammatory response itself is able to disrupt the epithelial integrity [24, 25]. Despite these intriguing findings, it seems that they are only part of the story, since none of those risk factors alone is sufficient to cause IBD. Instead, it is likely that imbalances in the host immune response lead to the morbid hyperinflammation in IBD.

A strong hint to a dysregulated immune response was the discovery of IBD1 mutations on chromosome 16 in CD. NOD2, product of IBD1, is an intracellular protein that activates NFκB in response to bacterial fragments. A leucine-rich repeat domain with regulatory and sensory functions was shown to be affected by missense and frameshift mutations in a subset of CD patients and was associated with early onset, predominantly ileal and fibrostenotic disease. Furthermore, these mutations could also predict the phenotype of CD [26–30]. On a functional level, two different mechanisms could be learned from mouse models. NOD2 deficiency led to MDP resistance of macrophages and a reduced production of defensins by Paneth cells, suggesting a reduced mucosal defense against luminal bacteria. On the other hand, mice with the human-like frameshift mutation mentioned above were highly susceptible to DSS-induced colitis with marked increase in intestinal inflammation and NFκB activation, suggesting a dysregulation of the immune response after injury of the mucosal barrier. The normal intestinal macrophages, instead, are typically of a non-inflammatory phenotype focused on the phagocytosis and clearance of bacteria [31]. At the same time, none of these models above spontaneously developed intestinal inflammation [32–34]. NOD2 alterations were the first example of alterations in the innate immediate immune response with subsequent discovery of many more. NOD2 belongs to the family of pattern recognition receptors (PRRs), highly conserved receptors for pathogen- and danger-associated molecular patterns (PAMP/DAMP). The PRRs that include the families of RLRs, TLRs, CLRs, NLRs, and others are activated by those PAMPs and DAMPs, triggering an immediate innate immune response. Therefore, they are one of the front links between a pathogen and the host response, some of them have been linked to IBD [35], and are a target of new drugs that are tested in clinical trials (NCT03178669).

One of the key mechanisms of symbiosis between host and intestinal microbiome is immune tolerance, and this central concept of living together seems to be disrupted in IBD. Rare cases of inherited monogenetic disorders lead to IBD-like diseases in humans, for example, mutations in FOXP3, IL10, IL10R, or XIAP. For all of those, a mechanistic link to immune tolerance exists [36]. As outlined above, normal lamina propria macrophages effectively eliminate intruding bacteria without calling for much inflammation; they begin to secrete anti-inflammatory mediators upon bacterial activation [37]. Contrarily, in IBD, myeloid cells of the lamina propria react with a solid proinflammatory response upon stimulation with microbial substances [10, 38, 39]. The switch between tolerance and inflammation is flipped in part by the dendritic cells of the lamina propria in a WNT-dependent fashion [40]. Taken together, the myeloid cells as the first line of defense overreact in IBD. Bridging to the adaptive response, there are also changes in the more recently discovered innate lymphoid cells of the gut. Expansion of ILC1 and NCR-ILC3 cells leads to loss of protective IL-22 and augmented inflammatory IL-17 production [41–45]. The adaptive lymphoid reaction, mainly responsible for the chronic inflammatory reaction, is altered in a harmful way, too. Normal gut-associated lymphoid tissue does not react to commensal bacteria with an intense inflammatory response, but instead actively clears T cells specific to commensal bacteria, a process that is damaged in IBD [46]. There is a growing number of types of lymphocytes discovered as being involved in the inflammation in IBD, accompanied by even more cytokines that are secreted [47]. Th1 mainly react to intracellular pathogens, activating cellular immune response, and are induced by IL-12 and IL-18; both are highly expressed in CD by activated macrophages. The Th1 cells, in turn, then produce IFNγ, also detected in high levels in the inflamed CD mucosa; IFNγ is considered one of the driver cytokines in CD [48–51]. Th2 cells are drivers of humoral immunity and mount reactions to parasites and are involved in allergic reactions; the main cytokines produced are IL-4, IL-5, and IL-13. Because of high levels of IL-5 and IL-13 in UC, this IBD was assumed to be mainly Th2-driven. However, doubts emerged from the absence of increased IL-4 production and missing evidence for a pathogenetic role of IL-13. Moreover, it was shown that IL-13 is more likely produced by NKT cells in UC [52–55]. Furthermore, while it was assumed in earlier studies that IL-13 drives fibrosis and is the key cytokine in UC, conflicting evidence
for this could be found in studies in IBD patients [56–61]. With respect to the oxazolone- and TNBS-induced colitis mouse models, Th1 and Th2 reactions were seen differentially involved; the Th1 response was considered to be more pronounced in TNBS colitis, which resembles some features of CD, whereas the Th2-dependent inflammation was seen in oxazolone colitis, sharing some features with UC [51, 53–55, 58]. Regrettably, targeting neither of IFN\(\gamma\) nor of IL-13 and thereby selectively targeting Th1 or Th2 response, respectively, were convincingly effective in treating UC or CD. Therefore, it seems that both pathways can stand in for and control each other [53, 58, 62]. Important progress in the decryption of IBD pathogenesis was made with the discovery of Th17 cells, a type of Th cells producing IL-17A that has been accused to be potently proinflammatory and furthermore being involved in fibrogenesis and MMP production [48, 63–65]. Among further lymphocytes involved in IBD pathogenesis, like Th9, NKT, MAIT, or ILC cells, being far beyond the scope of this review, regulatory T cells and their role in IBD pathogenesis have been established [80, 81] and link IBD with additional signaling pathways including autophagy and endoplasmic reticulum stress signaling, but these are again beyond the scope of this review.

2. Animal Models of IBD

Much of the knowledge about the immune mechanisms in IBD has been learned from mouse models, but some merits and demerits of these models must be considered. Observing the gut immune response in a whole organism has the advantage that all players of this complex game are in, and therefore, their context-specific action can be explored. However, harsh exogenous or genetic measures must be taken to induce IBD-like disease in mice, which unlikely resemble the factors leading to human disease. Therefore, many mouse models have been developed, and each of them is thought to mirror one piece of the pathogenesis. The most human-like models are congenic models, which are difficult to establish. In some chemical models, extrinsic substances damage the gut epithelium and provoke mainly an acute, innate response of inflammation and repair that can be studied but lack the chronic inflammation that is typically found in IBD; in other cases, gut proteins are modified by hapteneating agents and trigger an immune response. Mono- or oligogenic models shed light onto the specifically targeted pathway but are unlikely to resemble the complex mechanisms in human disease. Finally, adoptive immune transfer models are used mainly to unravel the interaction of lymphocytes [82]. Most of the models develop colitis, and there are only few models with small intestine disease.

2.1. Chemical Models: DSS Colitis. First described in 1990 [83, 84], DSS colitis is one of the most frequently used models of IBD. Usually, mice with BALB/c or C57BL/6 background are given 1.5–5% dextran sodium sulfate (DSS) in their drinking water. After some days (typically 6–10 days), the mice develop diarrhea, gross rectal bleeding, and weight loss; the reason for this is an ulcerating acute colitis with infiltration of neutrophil granulocytes. The exact mechanism of action of DSS is not known, but it leads to damage of the epithelial monolayer with increased permeability for luminal bacterial compounds. This acute colitis depends on luminal bacteria, but does not depend on the adaptive immune response, as shown in RAG2-KO or SCID mice [85, 86]. Therefore, this model was most useful in exploring the innate immune response, including the TLR- and inflammasome-dependent pathways [87, 88] as well as macrophage and neutrophil contributions. This has led to some unexpected findings. Since TLRs and MyD88 have well-known inflammatory properties, the increased epithelial permeability in DSS colitis would be expected to lead to TLR activation and therefore to a more severe inflammation. However, mice lacking TLR2, TLR4, or MyD88 developed even more severe inflammation [89], pointing to a regenerative and protective as well as immunomodulating effect of these proteins [90, 91]. The mechanisms of regeneration, then, can also be studied in the DSS colitis model and have led to the discovery of the involvement of GM-CSF, Wnt pathway, and IL-18 or IL-33 [92–95]. Evidence from the DSS colitis model has led to interests in the development of anti-IL-18 therapy [96], which will be evaluated in clinical trials (NCT03681067). Furthermore, the interplay of host and microbiome in colitis has been studied in this model [97]. One interesting modification of the DSS colitis model is the administration of azoxymethane before inducing DSS colitis. In this model, mice develop premalignant and malignant colorectal lesions, serving as a mirror for UC-associated colorectal cancer [98].

2.2. Chemical Models: Haptenating Agents. In these models, topical administration of a chemical agent leads to a modification of intestinal proteins triggering an immune response. Therefore, adaptive immune response is involved, although it has been shown that innate mechanisms are essential in these models, too [99, 100]. In the TNBS colitis model, trinitrobenzene sulfonic acid (TNBS) is applied directly into the colon in a mixture with ethanol that allows the TNBS to cross the epithelial barrier. Mice then develop severe diarrhea, a wasting syndrome and rectal prolapse with maximum severity after about 3 weeks [99]. In this model, some CD-like features as transmural
inflammation, fibrosis, and an IFNy- and Th1-dominant inflammation can be found. In its first publication, the essential contribution of IL-12 was already shown, with important therapeutic implications [101]. Since this first description was based on targeting of p40 and therefore suppressing IL-12 and IL-23 action, the contribution of each of those cytokines is still not completely understood in human disease, but in TNBS colitis, suppressing IL-23 unleashes IL-12 production via IL-17A and T-bet and therefore exacerbates colitis; so in this model, Th1 action seems to dominate [102, 103]. Subsequently, IL-12 and IL-23 were found to be the key regulators of Th17 differentiation. In a bedside setting, despite strong experimental evidence, disruption of IL-17A signaling by anti-IL-17A antibody secukinumab led to acute exacerbations of CD [104, 105]. While summa summarum, this cytokine therefore seems to have a rather protective function; targeting the Th17 differentiation was far more successful. Th17 cells differentiate under the influence of IL-23, IL-1β, IL-6, and TGF-β [106]. Targeting p40, a subunit of IL-12 and IL-23, by ustekinumab showed significant effects in two RCT of MC patients and is approved for therapy [107]. Risankizumab, targeting specifically IL-23, showed promising results in earlier clinical trials [108, 109]. One more recently described cytokine, TL1a, is involved in TNBS colitis and associated fibrosis and has recently been found to be a beneficial target in IBD models, including treatment of fibrosis [110]. PF-06480605, a TL1a targeting agent, is currently under clinical phase II evaluation (NCT02840721). Adhesion molecules of the alpha-4-integrin pathway have been evaluated in the treatment of IBD, but unfortunately, unspecific block of alpha-4-integrin by natalizumab led to reports of lethal viral encephalopathy. The α4β7-integrin-MAdCAM-1 pathway was subsequently identified as the gut-selective subtype of leucocyte adhesion, and interference showed a significant therapeutic effect in TNBS colitis [111], eventually leading to the development of vedolizumab, an α4β7-integrin antibody approved for IBD therapy. TNBS can be used to provoke a more acute colitis as described above or induce a chronic colitis, when repeatedly administered in low doses. Importantly, this chronic inflammation is also self-limited despite continued TNBS application and gives insights into the mechanisms of acquired immune tolerance [112–114].

Oxazolone is another such agent and is also administered topically. The colitis evoked by oxazolone is superficial, leading to edema and ulcers as well as neutrophil and lymphocyte infiltration; therefore, it has many similarities with UC [53, 115]. Both oxazolone colitis and UC are characterized by increased IL-9 and IL-13 production [116]; the latter has been shown to be essential in oxazolone colitis and is produced by the equally essential NKT cells. Differences between the model and the disease became apparent, however, when targeting IL-13 in UC failed to ameliorate disease activity. Anrnikizumab and tralokinumab, monoclonal antibodies against IL-13, as well as QAX576, an IL-13 inhibitor, reached the phase II and phase I level of clinical evaluation for UC and CD, and further evaluation was discontinued because of discouraging results [57, 59, 117].

2.3. Mono- and Oligogenetic Models. There is a number of genetically engineered mice that develop spontaneous inflammation of the gut and are used as models for IBD [118]. Because of the highly specific alteration in these mice, the functional involvement of the target gene can be explored quite exactly, but these mice are less likely to resemble the human IBD. Altering genes involved in epithelial cell homeostasis and barrier function, mucin components, or anti-inflammatory pathways lead to spontaneous inflammation of the gut [119–126]. For example, mice with IL-10 deficiency spontaneously develop colitic inflammation. Notably, some genetic models with a terminal ileitis and even skip lesions have been developed, resembling the most common distribution of inflammation in CD [127–131].

2.4. Adoptive Transfer Colitis. When naïve lymphocytes from syngenic donors are transferred to a SCID- or Rag1−/− mouse, a severe colitis with weight loss develops. This is due to a lack of Tregs in this setting; transfer of mature Treg-containing lymphocytes or a cotransfer with Tregs prevents colitis [132]. Therefore, this adoptive transfer model is tremendously helpful for deciphering the mechanisms by which Tregs suppress inflammation [133]. Basically, by introducing further genetic modifications into donor or recipient mice, involvement of these genes can be shown; for example, the involvement of IL-10 and TGFβ in the regulatory T cell function could be shown: disruption of IL-10, its receptor IL-10Rβ, TGFβ, or expression of a dominant negative TGFβ-receptor led to a loss of the suppressive action of Treg transfer in this model [134–137]. Further knowledge about Treg induction and stability by IL-23 and IL-33 has been demonstrated in this model [138, 139]. Furthermore, the essential contributions of IFNy and of the Th17 response for developing transfer colitis could be shown using this approach by jamming T-bet or IL-23 and IL-17, respectively [140–143]. Despite the strong experimental evidence for IFNy as a key driver of inflammation, targeting IFNy in the clinical setting was not successful, as a phase II trial of fontolizumab, an anti-IFNy-antibody, failed to meet the primary endpoint [144], but this study showed significant efficacy after longer treatment. SMAD7, a negative regulator of the TGFβ pathway overexpressed in IBD, was evaluated as a therapeutic target using the adoptive transfer colitis model [69], and moneersen, a SMAD7 antisense oligonucleotide, showed promising results in phase II trials; unfortunately, the phase III trial lacked emerging benefit, leading to its termination (NCT02596893). One further important finding in this model was the plasticity of the Th response. Th17 cells were shown to be able to transdifferentiate to Th1 cells. Given this plasticity, we start to understand why some patients are not responsive to therapies targeting those different pathways specifically [75, 145].

2.5. Congenic Models. Some animal models develop an IBD-like phenotype spontaneously without a targeted intervention; they can be developed through specific breeding and since have a polygenetic and complex pathogenesis but therefore are thought to resemble human disease to the closest. One good example of this type of model is the SAMP1/YitFc
mouse strain [129]. The ancestors of these mice have been held in scientific hands since almost one century now, with dramatic changes in its phenotype from a leukemia prone to a premature senescent phenotype and now to the SAMP1/YitFc mouse. These mice spontaneously exhibit typical symptoms of CD-like skip lesions, ileitis, transmural and stricturing in inflammation, perianal fistulizing disease, and extraintestinal symptoms [121, 129, 146, 147]. Since this phenotype developed through untargeted recombination, the responsible genomic loci were unknown and candidate loci were confirmed through generation of congenic strains, meaning that mice differing in only few genomic loci were bred and the impact of these differences was studied. This approach led to the identification of at least 4 highly IBD phenotype-associated loci, with strongest evidence for a locus spanning genes for IL-10 receptor alpha and IL-18, and this locus overlaps with susceptibility loci discovered in the DSS and TNBS colitis models [148–150]. One major advantage of this model is that subliminal changes preceding the onset of overt IBD can be studied in detail; in this model, alterations in epithelial composition and permeability could be observed prior to the onset of inflammation, suggestive of a causal role [129]. The SAMP1/YitFc strain paralleled the clinically observed response to anti-TNFα treatment and gave insights in the mechanism of action of these drugs in IBD [151].

### 3. Organoids

The models described above are suitable for reflecting the complex mechanisms in a whole organism in an IBD-like condition, but need mice to be raised for weeks and to be killed and lack many of the conveniences of cultured cells, which are much easier to manipulate, to observe, and to analyze; furthermore, the murine origin can impair the validity for human disease. Cell cultures, on the other hand, mostly stem from malignant transformed cells, are therefore unlikely to reflect the behavior of healthy cells, especially if one keeps in mind that one of the hallmarks of malignant tumors is to stop forming an intact epithelial monolayer, whereas the integrity of the latter is one of the key focusses in IBD research. Primary epithelial cells do not form stable cultures in vitro, making their use difficult.

The cornerstone for circumvention of these problems was laid recently with the development of intestinal organoids. Organoids can now be raised from stem cells, either by differentiation of pluripotent stem cells or by culture of adult intestinal stem cells from isolated intestinal crypts under specific conditions. In 2009, Sato et al. published a report of successful differentiation of single murine intestinal stem cells towards crypt-villus domain containing spherical bodies, using specific culture conditions. The group had discovered a stem cell specific marker, Lgr5, before. These Lgr5+ cells then could be grown in a 3D basement membrane-like gel called Matrigel, which contains the secretion of a sarcoma cell line and contains many of the basement membrane proteins. Combined stimulation with R-spondin 1, EGF, and Noggin-like peptide then led to the formation of self-organizing bubble-like epithelial structures with crypt-villus domains, stem cells in the bottom of the crypt, Paneth cells, enteroendocrine cells, and goblet cells. Villi protruded into the lumen of these organoids, which was filled with apoptotic cells shedding from the villus tips. These organoids were stable in culture, and a closely related technique could be used to establish indefinitely growing organoids from human colonic epithelium [152–154]. Published in 2011, Spence et al. were able to direct the differentiation of human-induced pluripotent stem cells and embryonic pluripotent stem cells towards intestinal organoids containing all intestinal epithelial cell types, crypts, microvilli, and transepithelial substance transporting properties [155]. In short, Activin A induced the formation of definitive endoderm- (DE-) like cells from pluripotent stem cells. After 3 days of treatment, the cells had acquired the DE phenotype and were still able to form foregut and hindgut lineages. At this point of time, exposition to FGF4 and Wnt3a for 4 days led to stable induction of a hindgut phenotype. Cells formed tubes and budded off to hindgut spheroids; this resembled the embryonic hindgut formation closely. Those still cuboid, but on a molecular level clearly hindgut differentiated epithelial spheroids then matured in a Matrigel-based 3D culture system containing additional growth factors; this led to the formation of organoids resembling mature intestinal epithelium. In this model, even mesenchyme was formed. This pioneering work has now equipped scientists with a new model of intestinal epithelium that combines human origin, nonmalignant genetics, and accessibility to in vitro cell culture techniques as well as inclusion of all epithelial cell types present in normal epithelium including rare cells like M, Tuft, or enteroendocrine cells [156–158]. The latter is of importance, since these cells have been implicated in IBD pathogenesis but are difficult to assess in other models [159–161]. Furthermore, and unlike embryonic stem cells, this model can be generated easily from affected individuals as well as healthy controls, since only a small mucosal biopsy is needed and therefore is of lesser ethical concern. While organoids from iPSCs are of great interest in other fields of research, organoids from intestinal adult stem cells carry the advantage of genetic and epigenetic stability relative to the site of origin, while differentiation of iPSCs is linked to genetic and epigenetic variation [159–163]. These organoids are a relatively new tool, and some challenges must be encountered in the future. Pure epithelial organoids will barely be suitable to investigate interactions with other cell types, so modelling fibrosis or immune cell and vascular or neuronal interactions need a more complex model. Accordingly, coculture with other cell types has been developed. Nozaki et al. were able to add intraepithelial lymphocytes (IELs) to murine intestinal organoids, maintain these in culture, and perform stimulation and motility experiments on them. Culture of IELs was not possible before, and therefore, intestinal organoids opened the window for detailed research on IELs [164, 165]. Pastula et al. successfully added fibroblasts and enteric nerves to these models and therefore were able to modulate the intestinal stem cell niche more precisely, giving the opportunity for the investigation of the role of these interactions in carcinogenesis or wound healing [166].
coclure system adding macrophages was developed by Noel et al. In this model, importantly, an increase in mucosal barrier function and interactions of epithelial cells and macrophages were observed, and a coordinated response to pathogenic strains of *E. coli* could be shown in vitro [167]. In this latter work, the bubble-like organoids were grown in polarized 2D cultures, as it had been developed before [168]. This is of great importance, since in the bubble-like structures access to the apical surface of the artificial epithelium is difficult, but as outlined above, the luminal contents of the bowel are thought to be indispensable for IBD pathogenesis. In these 2D cultures, however, both sides of the artificial epithelium are directly accessible; furthermore, the growth on a liquid-air interface has been shown to be important for gene expression. These 2D cultures were shown to develop abilities similar to the gut epithelium, like IgA transcytosis, peptide absorption, or polarized cytokine secretion [169]. Furthermore, interaction with apical bacteria and viruses has already been modulated [168, 170–172]. Adding even more complexity, microfluidic organ-on-a-chip models have been developed, adding vascular cells, bacterial flora, and even flow and mechanical forces like in human bowel to the model; these highly developed systems are very promising for the development of pharmacological high-throughput compound screening [173].

Rare forms of IBD, especially those with very early onset in early childhood, are caused by monogenetic aberrations, for example, in IL-10, IL-10R, XIAP, NCF2, or TTC7 [174]. Growing organoids from these young patients can help understand the role of those genes, as it was recently the case with caspase 8 [175] or NOX1 defects [176], but did also lead to the discovery of compounds that were able to reverse the morbid consequences of those mutations. For example, intestinal organoids grown from children with multiple intestinal atresia, a rare congenital condition with IBD-like features, showed an inverted growth with the cells apical side on the outside of the organoids; treatment with a Rho kinase inhibitor led to reversal of this inversion and could help in the development of new therapies for this condition [177]. Besides those monogenetic conditions, more than 200 risk loci have been found associated with IBD. In addition to the frequently used genetically manipulated mice, intestinal organoids are increasingly used to elucidate the role of the IBD-associated genes. For example, the interplay of IL-22 and the risk gene ATG16L1 was recently discovered using intestinal organoids [178]. Hohwieler et al. have recently described the generation of induced human intestinal organoids (iHIOs) derived from a patient with a severe course of CD. These organoids were derived from keratinocytes via generation of induced pluripotent stem cells and subsequent stepwise directed differentiation towards intestinal organoids. No significant differences between patient derived and control cells from healthy donors could be observed within the course of directed differentiation from iPSCs towards iHIOs. Upon continued organoid culture, a decreased amount of goblet cells could be observed. This aspect may rise interest as defective goblet cell differentiation has previously been described for UC [179] (see Figure 1).

As described above, common IBDs are thought to be multifactorial diseases with a polygenetic predisposition; there is a lack of models with an authentic epigenetic background. Organoid cultures have been successfully established from the inflamed mucosa of IBD patients; subsequent analyses have proven that transcriptional signatures of inflamed epithelial structures may persist within descending organoids [180, 181]. Therefore, organoid-based models of IBD open further fields of research for scientists: epigenetic changes have recently been involved in IBD pathogenesis [182–186]. Howell et al. then showed in a very robust study that besides site-specific epigenetic imprints, there are disease-specific epigenetic alterations in pediatric IBD epithelial cells at disease onset and these seem to persist even after the inflammation passed by. Importantly, many of the epigenetic changes observed in IBD correlate with known genetic susceptibility loci. Epigenetic alterations are difficult to analyze on a functional level, but importantly, the group was also able to show that organoids derived from these IBD patients retained their epigenetic characteristics. Therefore, intestinal organoids derived from affected individuals could be new promising models to investigate the effects of these epigenetic changes on a functional level and the influence of novel therapeutics on them [187]. Vice versa, since heterotopic transplant experiments in mice have shown phenotypical stability of intestinal organoids even after transplant in another bowel segment, healthy organoids could be a first step to a “mucosal transplant” for IBD [188–190].

Latest work from the Jonkers Lab illustrates additional options of organoid-based disease modelling in IBD research: patient-derived organoids displayed an effective epithelial barrier. Significant disruption of the epithelial barrier function could be induced by EGTA: diffusion of fluorescein isothiocyanate-labelled dextran of 4kDa (FITC-D4) towards the intestinal organoids lumen was markedly increased in IBD-derived organoids upon EGTA exposure analog, the lines of Caco-2 cell monolayers. These findings suggest that intestinal organoids might have substantial value for disease modelling of disturbed epithelial barriers [181].

Many important laboratory techniques have been used on organoids with success. Since freezing and thawing techniques also work for organoids, van de Watering et al. started up a “living biobank” with cryopreserved organoids from colorectal cancers and associated normal epithelium. As the authors outline, this could be of high importance for drug development and ex vivo drug susceptibility testing for patients with CRC [191], and the same could be true for patients with IBD and other epithelial gut diseases. Given the stability of organoid cultures, even high-throughput compound screening seems possible (Figure 2). Genetic editing and gene silencing have also been performed successfully in organoid cultures [192–195], making this model even more versatile.

Extensive fibrosis is one of the major complications of CD. The mechanisms behind this process are deciphered only in part, and using in vitro organoid models could prove to be helpful. As described above, this mesenchymal reaction could be modelled by raising intestinal organoids from PSCs or by coculture with mesenchymal cells, but recently,
epithelial to mesenchymal transition (EMT) was induced in intestinal organoids from mice, and TGFβ and TNFα were shown to induce this EMT [196]; both cytokines have been implicated in IBD pathogenesis. Further development of this model could be helpful for understanding the process of fibrosis in an IBD background.

4. Conclusions

Inflammatory bowel diseases cause high morbidity and substantial costs. Our knowledge about the causes of those diseases is rapidly growing, leading to new therapeutic options, but since still not every IBD can be controlled today,
Further work is needed to understand the complex pathogenesis and find novel treatments. Much of our current knowledge comes from mouse models, genomic association studies, and rare monogenetic conditions with an IBD-like phenotype; in addition, molecular studies have been performed in vitro, mostly using transformed epithelial cell lines, because primary intestinal epithelial cells could not be grown in a stable culture. Progress in the exploration of the pathogenesis was hampered by some substantial disadvantages of the models, which had genetic differences due to malignant or murine origin, were time-consuming to create, difficult to manipulate, and hardly accessible for high-throughput or living tissue setups. The recent development of intestinal organoid cultures that can be easily derived from healthy or affected persons and manipulated with any laboratory in vitro method overcame those disadvantages and adds a highly promising model to the benches of scientists and has already led to new insights into the puzzle of IBD. Future applications could be the development of high-throughput drug screening assays.

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this paper.

**References**

[1] M. D. Rutter, B. P. Saunders, K. H. Wilkinson et al., "Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis," *Gastroenterology*, vol. 130, no. 4, pp. 1030–1038, 2006.

[2] S. C. Ng, H. Y. Shi, N. Hamidi et al., "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies," *The Lancet*, vol. 390, no. 10114, pp. 2769–2778, 2018.

[3] D. Laharie, S. Debeugny, M. Peeters et al., "Inflammatory bowel disease in spouses and their offspring," *Gastroenterology*, vol. 120, no. 4, pp. 816–819, 2001.

[4] T. Bernklev, J. Jahnsen, I. Lygren, M. Henriksen, M. Vatn, and B. Moum, "Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms," *Inflammatory Bowel Diseases*, vol. 11, no. 10, pp. 909–918, 2005.

[5] I. C. Solberg, I. Lygren, J. Jahnsen et al., "Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study)," *Scandinavian Journal of Gastroenterology*, vol. 44, no. 4, pp. 431–440, 2009.

[6] I. C. Solberg, M. H. Vatn, O. Høsie et al., "Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study," *Clinical Gastroenterology and Hepatology*, vol. 5, no. 12, pp. 1430–1438, 2007.

[7] A. P. Yu, L. A. Cabanilla, E. Q. Wu, P. M. Mulani, and J. Chao, "The costs of Crohn’s disease in the United States and other Western countries: a systematic review," *Current Medical Research and Opinion*, vol. 24, no. 2, pp. 319–328, 2008.

[8] F. Mehta, "Report: economic implications of inflammatory bowel disease and its management," *The American Journal of Managed Care*, vol. 22, Supplement 3, pp. s51–s60, 2016.
[9] J. M. Reimund, C. Wittersheim, S. Dumont et al., "Increased production of tumour necrosis factor-α and interleukin-1β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease," *Gut*, vol. 39, no. 5, pp. 684–689, 1996.

[10] H. C. Reinecker, M. Steffen, T. Witthoeft et al., “Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease,” *Clinical and Experimental Immunology*, vol. 94, no. 1, pp. 174–181, 1993.

[11] L. Diaanda, A. M. Hanby, N. A. Wright, A. Sebesteny, A. C. Hayday, and M. J. Owen, "T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment," *The American Journal of Pathology*, vol. 150, no. 1, pp. 91–97, 1997.

[12] M. Schultz, S. L. Tonkonogy, R. K. Sellon et al., "IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 276, no. 6, pp. G1461–G1472, 1999.

[13] R. K. Sellon, S. Tonkonogy, M. Schultz et al., “Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice,” *Infection and Immunity*, vol. 66, no. 11, pp. 5224–5231, 1998.

[14] E. R. Lane, T. L. Zisman, and D. L. Suskind, “The microbiota in inflammatory bowel disease: current and therapeutic insights,” *Journal of Inflammation Research*, vol. 10, pp. 63–73, 2017.

[15] C. Schultz, F. M. van den Berg, F. W. ten Kate, G. N. J. Tytgat, and J. Dankert, “The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls,” *Gastroenterology*, vol. 117, no. 5, pp. 1089–1097, 1999.

[16] D. K. Podolsky and K. J. Isselbacher, "Composition of human colonic mucin. Selective alteration in inflammatory bowel disease," *The Journal of Clinical Investigation*, vol. 72, no. 1, pp. 142–153, 1983.

[17] J. Wyatt, H. Vogelsang, W. Hubl, T. Waldhoer, and H. Lochs, "Intestinal permeability and the prediction of relapse in Crohn’s disease," *The Lancet*, vol. 341, no. 8858, pp. 1437–1439, 1993.

[18] C. A. Anderson, G. Boucher, C. W. Lees et al., "Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47," *Nature Genetics*, vol. 43, no. 3, pp. 246–252, 2011.

[19] UK IBD Genetics Consortium and The Wellcome Trust Case Control Consortium 2, "Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region," *Nature Genetics*, vol. 41, no. 12, pp. 1330–1334, 2009.

[20] K. L. VanDussen, C. T. Liu, D. Li et al., "Genetic variants synthesize to produce Paneth cell phenotypes that define subtypes of Crohn’s disease," *Gastroenterology*, vol. 146, no. 1, pp. 200–209, 2014.

[21] M. Camus, S. Esses, B. Pariente et al., "Oligoclonal expansions of mucosal T cells in Crohn’s disease predominate in NKG2D-expressing CD4 T cells," *Mucosal Immunology*, vol. 7, no. 2, pp. 325–334, 2014.

[22] C. A. Rubio and P. T. Schmidt, "Severe defects in the macrophage barrier to gut microflora in inflammatory bowel disease and colon cancer," *Anticancer Research*, vol. 38, no. 7, pp. 3811–3815, 2018.

[23] L. Mayer and R. Shlien, “Evidence for function of la molecules on gut epithelial cells in man,” *The Journal of Experimental Medicine*, vol. 166, no. 5, pp. 1471–1483, 1987.

[24] R. M. Al-Sadi and T. Y. Ma, “IL-1β causes an increase in intestinal epithelial tight junction permeability,” *The Journal of Immunology*, vol. 178, no. 7, pp. 4641–4649, 2007.

[25] M. Bruewer, A. Luegering, T. Kucharzik et al., “Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms,” *The Journal of Immunology*, vol. 171, no. 11, pp. 6164–6172, 2003.

[26] A. P. Cuthbert, S. A. Fisher, M. M. Mirza et al., “The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease,” *Gastroenterology*, vol. 122, no. 4, pp. 867–874, 2002.

[27] J. Hampe, J. Grebe, S. Nikolaus et al., “Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study,” *Lancet*, vol. 359, no. 9138, pp. 1661–1665, 2002.

[28] J. P. Hugot, M. Chamaillard, H. Zouali et al., “Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease,” *Nature*, vol. 411, no. 6837, pp. 599–603, 2001.

[29] Y. Ogura, D. K. Bonen, N. Inohana et al., “A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease,” *Nature*, vol. 411, no. 6837, pp. 603–606, 2001.

[30] S. Vermeire, G. Wild, K. Kocher et al., “CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure,” *American Journal of Human Genetics*, vol. 71, no. 1, pp. 74–83, 2002.

[31] L. E. Smythies, M. Sellers, R. H. Clements et al., “Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bactericidal activity,” *The Journal of Clinical Investigation*, vol. 115, no. 1, pp. 66–75, 2005.

[32] K. S. Kobayashi, M. Chamaillard, Y. Ogura et al., “NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract,” *Science*, vol. 307, no. 5710, pp. 731–734, 2005.

[33] S. Maeda, L. C. Hsu, H. Liu et al., “Nod2 mutation in Crohn’s disease potentiates NF-kB activity and IL-1β processing,” *Science*, vol. 307, no. 5710, pp. 734–738, 2005.

[34] J. Wehkamp and E. F. Stange, “NOD2 mutation and mice: no Crohn’s disease but many lessons to learn,” *Trends in Molecular Medicine*, vol. 11, no. 7, pp. 307–309, 2005.

[35] D. Corridoni, T. Chapman, T. Ambrose, and A. Simmons, “Emerging mechanisms of innate immunity and their translational potential in inflammatory bowel disease,” *Frontiers in Medicine*, vol. 5, p. 32, 2018.

[36] H. H. Uhlig, T. Schwierd, S. Koletzko et al., “The diagnostic approach to monogenic very early onset inflammatory bowel disease,” *Gastroenterology*, vol. 147, no. 5, pp. 990–1007.e3, 2014.

[37] T. L. Denning, Y. C. Wang, S. R. Patel, I. R. Williams, and B. Pulendran, “Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses,” *Nature Immunology*, vol. 8, no. 10, pp. 1086–1094, 2007.

[38] C. C. Bain, C. L. Scott, H. Uronen-Hansson et al., “Resident and pro-inflammatory macrophages in the colon represent...
alternative context-dependent fates of the same Ly6Chi monocyte precursors,” Mucosal Immunology, vol. 6, no. 3, pp. 498–510, 2013.

[39] N. Kamada, T. Hisamatsu, S. Okamoto et al., “Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis,” The Journal of Clinical Investigation, vol. 118, no. 6, pp. 2269–2280, 2008.

[40] S. Manicassamy, B. Reizis, R. Ravindran et al., “Activation of β-catenin in dendritic cells regulates immunity versus tolerance in the intestine,” Science, vol. 329, no. 5993, pp. 849–853, 2010.

[41] B. Ahluwalia, L. Moraes, M. K. Magnusson, and L. Ohman, “Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies,” Scandinavian Journal of Gastroenterology, vol. 53, no. 4, pp. 379–389, 2018.

[42] J. H. Bernink, C. P. Peters, M. Munneke et al., “Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues,” Nature Immunology, vol. 14, no. 3, pp. 221–229, 2013.

[43] S. Buonocore, P. P. Ahern, H. H. Uhlig et al., “Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology,” Nature, vol. 464, no. 7293, pp. 1371–1375, 2010.

[44] M. Ebbo, A. Crinier, F. Vely, and E. Vivier, “Innate lymphoid cells: major players in inflammatory diseases,” Nature Reviews Immunology, vol. 17, no. 11, pp. 665–678, 2017.

[45] A. Geremia, C. V. Arancibia-Cárcamo, M. P. P. Fleming et al., “IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease,” The Journal of Experimental Medicine, vol. 208, no. 6, pp. 1127–1133, 2011.

[46] M. R. Hepworth, T. C. Fung, S. H. Masur et al., “Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells,” Science, vol. 348, no. 6238, pp. 1031–1035, 2015.

[47] P. Giuffrida, G. R. Corazza, and A. Di Sabatino, “Old and new lymphocyte players in inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 63, no. 2, pp. 277–288, 2018.

[48] F. Zorzi, I. Monteleone, M. Sarra et al., “Distinct profiles of effector cytokines mark the different phases of Crohn’s disease,” PLoS One, vol. 8, no. 1, article e54562, 2013.

[49] G. Monteleone, F. Trapano, T. Parrrello et al., “Bioactive IL-18 expression is up-regulated in Crohn’s disease,” The Journal of Immunology, vol. 163, no. 1, pp. 143–147, 1999.

[50] W. Strober and I. J. Fuss, “Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 6, pp. 1756–1767.e1, 2011.

[51] G. Monteleone, L. Biancone, R. Marasco et al., “Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells,” Gastroenterology, vol. 112, no. 4, pp. 1169–1178, 1997.

[52] M. Boirivant, I. J. Fuss, A. Chu, and W. Strober, “Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4,” The Journal of Experimental Medicine, vol. 188, no. 10, pp. 1929–1939, 1998.

[53] I. J. Fuss, F. Heller, M. Boirivant et al., “Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis,” The Journal of Clinical Investigation, vol. 113, no. 10, pp. 1490–1497, 2004.

[54] I. J. Fuss, M. Neurath, M. Boirivant et al., “Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5,” The Journal of Immunology, vol. 157, no. 3, pp. 1261–1270, 1996.

[55] E. Breese, C. P. Braegger, C. J. Corrigan, J. A. Walker-Smith, and T. T. MacDonald, “Interleukin-2- and interleukin gamma-secreting T cells in normal and diseased human intestinal mucosa,” Immunology, vol. 78, no. 1, pp. 127–131, 1993.

[56] P. Biancheri, A. di Sabatino, F. Ammoscato et al., “Absence of a role for interleukin-13 in inflammatory bowel disease,” European Journal of Immunology, vol. 44, no. 2, pp. 370–385, 2014.

[57] S. Danese, J. Rudzinski, W. Brandt et al., “Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study,” Gut, vol. 64, no. 2, pp. 234–249, 2015.

[58] F. Heller, P. Florian, C. BojarSKI et al., “Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution,” Gastroenterology, vol. 129, no. 2, pp. 550–564, 2005.

[59] W. Reinsch, J. Panés, S. Khurana et al., “Anrunkizumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study,” Gut, vol. 64, no. 6, pp. 894–900, 2015.

[60] B. Vainer, O. H. Nielsen, J. Hender, T. Horn, and I. Kirman, “Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease,” Cytokine, vol. 12, no. 10, pp. 1531–1536, 2000.

[61] S. Fichtner-Feigl, C. A. Young, A. Kitani, E. K. Geissler, H. J. Schiltt, and W. Strober, “IL-13 signaling via IL-13Rα1 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis,” Gastroenterology, vol. 135, no. 6, pp. 2003–2013.e7, 2008.

[62] I. J. Fuss and W. Strober, “The role of IL-13 and NK T cells in experimental and human ulcerative colitis,” Mucosal Immunology, vol. 1, no. 1, pp. S31–S33, 2008.

[63] P. Biancheri, S. L. Pender, F. Ammoscato et al., “The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis,” Fibrogenesis & Tissue Repair, vol. 6, no. 1, p. 13, 2013.

[64] S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003.

[65] T. Sugihara, A. Kobori, H. Imaeda et al., “The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease,” Clinical and Experimental Immunology, vol. 160, no. 3, pp. 386–393, 2010.

[66] S. Dominitzki, M. C. Fantini, C. Neufert et al., “Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of Foxp3 in naive CD4+CD25+ T cells,” The Journal of Immunology, vol. 179, no. 4, pp. 2041–2045, 2007.

[67] L. Fahlen, S. Read, L. Gorelik et al., “T cells that cannot respond to TGF-β escape control by CD4+CD25+ regulatory T cells,” The Journal of Experimental Medicine, vol. 201, no. 5, pp. 737–746, 2005.

[68] M. C. Fantini, C. Becker, G. Monteleone, F. Pallone, P. R. Galle, and M. F. Neurath, “Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25+ T cells through Foxp3 induction and down-regulation of Smad7,” The Journal of Immunology, vol. 172, no. 9, pp. 5149–5153, 2004.

[69] M. C. Fantini, A. Rizzo, D. Fina et al., “Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated...
suppression,” *Gastroenterology*, vol. 136, no. 4, pp. 1308–1316.e3, 2009.

[70] A. Izcue, J. L. Coombes, and F. Powrie, “Regulatory lymphocytes and intestinal inflammation,” *Annual Review of Immunology*, vol. 27, no. 1, pp. 313–338, 2009.

[71] J. Maul, C. Loddenkemper, P. Mundt et al., “Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease,” *Gastroenterology*, vol. 128, no. 7, pp. 1868–1878, 2005.

[72] G. Monteleone, A. Kumberova, N. M. Croft, C. McKenzie, H. W. Steer, and T. T. MacDonald, “Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease,” *The Journal of Clinical Investigation*, vol. 108, no. 4, pp. 601–609, 2001.

[73] A. O’Garra and P. Vieira, “Regulatory T cells and mechanisms of immune system control,” *Nature Medicine*, vol. 10, no. 8, pp. 801–805, 2004.

[74] M. Saruta, Q. T. Yu, P. R. Fleshner et al., “Characterization of FOXP3CD4 regulatory T cells in Crohn’s disease,” *Clinical Immunology*, vol. 125, no. 3, pp. 281–290, 2007.

[75] Y. K. Lee, H. Turner, C. L. Maynard et al., “Late developmental plasticity in the T helper 17 lineage,” *Immunity*, vol. 30, no. 1, pp. 92–107, 2009.

[76] C. L. Maynard and C. T. Weaver, “Intestinal effector T cells in health and disease,” *Immunity*, vol. 31, no. 3, pp. 389–400, 2009.

[77] L. A. Zenewicz, A. Antov, and R. A. Flavell, “CD4 T-cell differentiation and inflammatory bowel disease,” *Trends in Molecular Medicine*, vol. 15, no. 5, pp. 199–207, 2009.

[78] L. Zhou, M. M. W. Chong, and D. R. Littman, “Plasticity of CD4+ T cell lineage differentiation,” *Immunity*, vol. 30, no. 5, pp. 646–655, 2009.

[79] H. Schmitt, U. Billmeier, W. Dieterich et al., “Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease,” *Gut*, 2018.

[80] L. Jostins, S. Ripke, R. K. Weersma et al., “Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease,” *Nature*, vol. 491, no. 7422, pp. 119–124, 2012.

[81] M. Mokry, S. Middendorp, C. L. Wiegerinck et al., “Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium,” *Gastroenterology*, vol. 146, no. 4, pp. 1040–1047, 2014.

[82] G. Bamias, K. O. Arsenneau, and F. Cominelli, “Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine,” *Current Opinion in Gastroenterology*, vol. 33, no. 6, pp. 411–416, 2017.

[83] H. S. Cooper, S. N. Murthy, R. S. Shah, and D. J. Sedergran, “Clinicopathologic study of dextran sulfate sodium experimental murine colitis,” *Laboratory Investigation*, vol. 69, no. 2, pp. 238–249, 1993.

[84] I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice,” *Gastroenterology*, vol. 98, no. 3, pp. 694–702, 1990.

[85] B. Chassang, J. D. Aitken, M. Malleshappa, and M. Vijay-Kumar, “Dextran sulfate sodium (DSS)-induced colitis in mice,” *Current Protocols in Immunology*, vol. 104, pp. 15.25.1–15.25.14, 2014.

[86] L. A. Dieleman, B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson, “Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice,” *Gastroenterology*, vol. 107, no. 6, pp. 1643–1652, 1994.

[87] E. Elinav, T. Strowig, A. L. Kau et al., “NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis,” *Cell*, vol. 145, no. 5, pp. 745–757, 2011.

[88] M. H. Zaki, K. L. Boyd, P. Vogel, M. B. Kastan, M. Lamkanfi, and T. D. Kanneganti, “The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis,” *Immunity*, vol. 32, no. 3, pp. 379–391, 2010.

[89] M. Fukata, K. S. Michelsen, R. Eri et al., “Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 288, no. 5, pp. G1055–G1065, 2005.

[90] E. Cario, G. Gerken, and D. K. Podolsky, “Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function,” *Gastroenterology*, vol. 132, no. 4, pp. 1359–1374, 2007.

[91] S. L. Pull, J. M. Doherty, J. C. Mills, J. I. Gordon, and T. S. Stappenbeck, “Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 1, pp. 99–104, 2005.

[92] L. Egea, C. S. McAllister, O. Lakhdari, I. Minev, S. Shenouda, and M. F. Kagnoff, “GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa,” *The Journal of Immunology*, vol. 190, no. 4, pp. 1702–1713, 2013.

[93] S. Koch, P. Nava, C. Addis et al., “The Wnt antagonist Dkk1 regulates intestinal epithelial homeostasis and wound repair,” *Gastroenterology*, vol. 141, no. 1, pp. 259–268.e8, 2011.

[94] M. A. K. Sedhom, M. Pichery, J. R. Murdoch et al., “Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice,” *Gut*, vol. 62, no. 12, pp. 1714–1723, 2013.

[95] B. Siegmund, G. Fantuzzi, F. Rieder et al., “Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production,” *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, vol. 281, no. 4, pp. R1264–R1273, 2001.

[96] H. Ishikura, T. Kanai, K. Uraushihara et al., “Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice,” *Journal of Gastroenterology and Hepatology*, vol. 18, no. 8, pp. 960–969, 2003.

[97] S. Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R. Medzhitov, “Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis,” *Cell*, vol. 118, no. 2, pp. 229–241, 2004.

[98] T. Tanaka, H. Kohno, R. Suzuki, Y. Yamada, S. Sugie, and H. Mori, “A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate,” *Cancer Science*, vol. 94, no. 11, pp. 965–973, 2003.

[99] S. Fiorucci, A. Mencarelli, B. Palazzetti et al., “Importance of innate immunity and collagen binding integrin αLβ1 in TNBS-induced colitis,” *Immunity*, vol. 17, no. 6, pp. 769–780, 2002.
C. Becker, H. Dornhoff, M. F. Neurath, I. Fuss, B. L. Kelsall, E. Stuber, and W. Strober, "Antibodies to interleukin 12 abrogate established experimental colitis in mice," The Journal of Experimental Medicine, vol. 182, no. 5, pp. 1281–1290, 1995.

C. Becker, H. Dornhoff, C. Neufert et al., "Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis," The Journal of Immunology, vol. 177, no. 5, pp. 2760–2764, 2006.

W. O’Connor Jr, M. Kamanaka, C. J. Booth et al., "A protective function for interleukin 17A in T cell-mediated intestinal inflammation," Nature Immunology, vol. 10, no. 6, pp. 603–609, 2009.

W. Hueber, B. E. Sands, S. Lewitzky et al., "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial," Gut, vol. 61, no. 12, pp. 1693–1700, 2012.

P. Miossec and J. K. Kolls, "Targeting IL-17 and TH17 cells in chronic inflammation," Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763–776, 2012.

E. Volpe, N. Servant, R. Zollinger et al., "A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human Th17 responses," Nature Immunology, vol. 9, no. 6, pp. 650–657, 2008.

B. G. Feagan, W. J. Sandborn, C. Gasink et al., "Ustekinumab as induction and maintenance therapy for Crohn’s disease," The New England Journal of Medicine, vol. 375, no. 20, pp. 1946–1960, 2016.

B. G. Feagan, W. J. Sandborn, G. D’Haens et al., "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study," The Lancet, vol. 389, no. 10080, pp. 1699–1709, 2017.

K. A. Papp, A. Blauvelt, M. Bukhalo et al., "Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis," The New England Journal of Medicine, vol. 376, no. 16, pp. 1551–1560, 2017.

A. W. Clarke, L. Poulton, D. Shim et al., "An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease," Mabs, vol. 10, no. 4, pp. 664–677, 2018.

A. Goto, Y. Aimura, Y. Shimomura, K. Imai, and Y. Hinoda, "Antisense therapy of MADCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis," Inflammatory Bowel Diseases, vol. 12, no. 8, pp. 758–765, 2006.

S. Fichtner-Feigl, R. Kesselring, M. Martin et al., "IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3β," The Journal of Immunology, vol. 192, no. 8, pp. 3969–3980, 2014.

I. J. Fuss, M. Boirivant, B. Lacy, and W. Strober, "The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis," The Journal of Immunology, vol. 168, no. 2, pp. 900–908, 2002.

M. F. Neurath, I. Fuss, B. L. Kelsall, D. H. Presky, W. Waegell, and W. Strober, "Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance," The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2605–2616, 1996.

F. Heller, I. J. Fuss, E. E. Nieuwenhuis, R. S. Blumberg, and W. Strober, "Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells," Immunity, vol. 17, no. 5, pp. 629–638, 2002.

K. Gerlach, Y. Hwang, A. Nikolaev et al., "TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells," Nature Immunology, vol. 15, no. 7, pp. 676–686, 2014.

E. Ramsden, P. Moulin, D. Lee, and A. D. Christ, QAX576, an Anti–Interleukin (IL)-13 Monoclonal Antibody, for the Treatment of Patients with Fistulising Crohn’s Disease (CD): Results of a Proof-of-Concept Study, United European Gastroenterology Week 2014, 2014.

P. Kiesler, I. J. Fuss, and W. Strober, "Experimental models of inflammatory bowel diseases," Cellular and Molecular Gastroenterology and Hepatology, vol. 1, no. 2, pp. 154–170, 2015.

W. S. Garrett, G. M. Lord, S. Punit et al., "Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system," Cell, vol. 131, no. 1, pp. 33–45, 2007.

R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, and W. Muller, "Interleukin-10-deficient mice develop chronic enterocolitis," Cell, vol. 75, no. 2, pp. 263–274, 1993.

S. Matsumoto, Y. Okabe, H. Setoyama et al., "Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain," Gut, vol. 43, no. 1, pp. 71–78, 1998.

A. Nenci, C. Becker, A. Wullaert et al., "Epithelial NEMO links innate immunity to chronic intestinal inflammation," Nature, vol. 446, no. 7135, pp. 557–561, 2007.

C. M. Panwala, J. C. Jones, and J. L. Viney, "A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis," The Journal of Immunology, vol. 161, no. 10, pp. 5733–5744, 1998.

K. Takeda, B. E. Clausen, T. Kaisho et al., "Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils," Immunity, vol. 10, no. 1, pp. 39–49, 1999.

A. Velich, W. Yang, J. Heyer et al., "Colorectal cancer in mice genetically deficient in the mucin Muc2," Science, vol. 295, no. 5560, pp. 1726–1729, 2002.

C. Zaph, A. E. Troy, B. C. Taylor et al., "Epithelial-cell-intrinsic IKK-β expression regulates intestinal immune homeostasis," Nature, vol. 446, no. 7135, pp. 552–556, 2007.

G. Bamias, M. I. Dahman, K. O. Arseneau et al., "Intestinal-specific TNFa overexpression induces Crohn’s-like ileitis in mice," PLoS One, vol. 8, no. 8, article e72594, 2013.

P. S. Hegan, S. K. Chandhoke, C. Barone, M. Egan, M. Bahlner, and M. S. Mooseker, "Mice lacking myosin IXb, an inflammatory bowel disease susceptibility gene, have impaired intestinal barrier function and superficial ulceration in the ileum," Cytoskeleton, vol. 73, no. 4, pp. 163–179, 2016.

T. T. Pizarro, L. Pastorelli, G. Bamias et al., "SAMPI/Yitfc mouse strain: a spontaneous model of Crohn’s disease-like ileitis," Inflammatory Bowel Diseases, vol. 17, no. 12, pp. 2566–2584, 2011.
Crohn’s disease-like ileitis,” The Journal of Experimental Medicine, vol. 214, no. 2, pp. 401–422, 2017.

[131] T. E. Adolph, M. F. Tomczak, L. Niederreiter et al., “Paneth cells as a site of origin for intestinal inflammation,” Nature, vol. 503, no. 7475, pp. 272–276, 2013.

[132] F. Powrie, M. W. Leach, S. Mauze, L. B. Caddie, and R. L. Coffman, “Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice,” International Immunology, vol. 5, no. 11, pp. 1461–1471, 1993.

[133] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008.

[134] C. Asseman, S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie, “An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation,” The Journal of Experimental Medicine, vol. 190, no. 7, pp. 995–1004, 1999.

[135] M. Murai, O. Turovskaya, G. Kim et al., “Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis,” Nature Immunology, vol. 10, no. 11, pp. 1178–1184, 2009.

[136] K. Nakamura, A. Kitani, and W. Strober, “Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β,” The Journal of Experimental Medicine, vol. 194, no. 5, pp. 629–644, 2001.

[137] F. Powrie, J. Carlino, M. W. Leach, S. Mauze, and R. L. Coffman, “A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells,” The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2669–2674, 1996.

[138] A. Izcue, S. Hue, S. Buonocore et al., “Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis,” Immunity, vol. 28, no. 4, pp. 559–570, 2008.

[139] C. Schiering, T. Krausgruber, A. Chomka et al., “The alarmin IL-33 promotes regulatory T-cell function in the intestine,” Nature, vol. 513, no. 7519, pp. 564–568, 2014.

[140] P. P. Ahern, C. Schiering, S. Buonocore et al., “Interleukin-23 drives intestinal inflammation through direct activity on T cells,” Immunity, vol. 33, no. 2, pp. 279–288, 2010.

[141] S. Hue, P. Ahern, S. Buonocore et al., “Interleukin-23 drives innate and T cell-mediated intestinal inflammation,” The Journal of Experimental Medicine, vol. 203, no. 11, pp. 2473–2483, 2006.

[142] M. Leppkes, C. Becker, I. I. Ivanov et al., “ROTY-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F,” Gastroenterology, vol. 136, no. 1, pp. 257–267, 2009.

[143] M. F. Neurath, B. Weigmann, S. Finotto et al., “The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease,” The Journal of Experimental Medicine, vol. 195, no. 9, pp. 1129–1143, 2002.

[144] W. Reinsch, W. de Villiers, L. Bene et al., “Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study,” Inflammatory Bowel Diseases, vol. 16, no. 2, pp. 233–242, 2010.

[145] T. Sujino, T. Kanai, Y. Ono et al., “Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells,” Gastroenterology, vol. 141, no. 3, pp. 1014–1023, 2011.

[146] M. M. Kosiewicz, C. C. Nast, A. Krishnan et al., “Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn’s disease,” The Journal of Clinical Investigation, vol. 107, no. 6, pp. 695–702, 2001.

[147] J. Rivera-Nieves, G. Bamias, A. Vidrich et al., “Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis,” Gastroenterology, vol. 124, no. 4, pp. 972–982, 2003.

[148] G. Bouma, A. Kaushiva, and W. Strober, “Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses,” Gastroenterology, vol. 123, no. 2, pp. 554–565, 2002.

[149] K. Kozaiwa, K. Sugawara, M. F. Smith Jr et al., “Identification of a quantitative trait locus for ileitis in a spontaneous mouse model of Crohn’s disease: SAMP1/YitFc,” Gastroenterology, vol. 125, no. 2, pp. 477–490, 2003.

[150] M. Mahler, I. J. Bristol, J. P. Sundberg et al., “Genetic analysis of susceptibility to dextran sulfate-induced colitis in mice,” Genomics, vol. 55, no. 2, pp. 147–156, 1999.

[151] M. Marini, G. Bamias, J. Rivera-Nieves et al., “TNF-α neutralization ameliorates the severity of murine Crohn’s-like ileitis by abrogation of intestinal epithelial cell apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8366–8371, 2003.

[152] T. Sato, D. E. Stange, M. Ferrante et al., “Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium,” Gastroenterology, vol. 141, no. 5, pp. 1762–1772, 2011.

[153] T. Sato, R. G. Vries, H. J. Snippert et al., “Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche,” Nature, vol. 459, no. 7244, pp. 262–265, 2009.

[154] P. Jung, T. Sato, A. Merlos-Suárez et al., “Isolation and in vitro expansion of human colonic stem cells,” Nature Medicine, vol. 17, no. 10, pp. 1225–1227, 2011.

[155] J. R. Spence, C. N. Mayhew, S. A. Rankin et al., “Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro,” Nature, vol. 470, no. 7332, pp. 105–109, 2011.

[156] N. W. Bellono, J. R. Bayer, D. B. Leitch et al., “Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways,” Cell, vol. 170, no. 1, pp. 185–198.e16, 2017.

[157] W. de Lau, P. Kujala, K. Schneeberger et al., “Peyer’s patch M cells derived from Lgr5 stem cells require SpiB and are induced by Rankl in cultured ‘miniguts’,” Molecular and Cellular Biology, vol. 32, no. 18, pp. 3639–3647, 2012.

[158] M. R. Hewitt, S. Lavoie, M. Michaud et al., “Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut,” Science, vol. 351, no. 6279, pp. 1329–1333, 2016.

[159] J. M. Cramer, T. Thompson, A. Geskin, W. LaFramboise, and E. Lagasse, “Distinct human stem cell populations in small and large intestine,” PLoS One, vol. 10, no. 3, article e0118792, 2015.

[160] J. Kraiczy, K. M. Nayak, K. J. Howell et al., “DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development,” Gut, vol. 68, no. 1, pp. 49–61, 2018.

[161] S. Middendorp, K. Schneeberger, C. L. Wiggerinck et al., “Adult stem cells in the small intestine are intrinsically
programmed with their location-specific function,” *Stem Cells*, vol. 32, no. 5, pp. 1083–1091, 2014.

[162] G. Liang and Y. Zhang, “Genetic and epigenetic variations in iPSCs: potential causes and implications for application,” *Cell Stem Cell*, vol. 13, no. 2, pp. 149–159, 2013.

[163] I. Dotti and A. Salas, “Potential use of human stem cell-derived intestinal organoids to study inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 24, no. 12, pp. 2501–2509, 2018.

[164] K. Nozaki, W. Mochizuki, Y. Matsumoto et al., “Co-culture with intestinal epithelial organoids allows efficient expansion and maturation analysis of intraepithelial lymphocytes,” *Journal of Gastroenterology*, vol. 51, no. 3, pp. 206–213, 2016.

[165] A. Rogoz, B. S. Reis, R. A. Karssmeijer, and D. Mucida, “A 3-D enteroid-based model to study T-cell and epithelial cell interaction,” *Journal of Immunological Methods*, vol. 421, pp. 89–95, 2015.

[166] A. Pastula, M. Middelhoj, A. Brandtner et al., “Three-dimensional gastrointestinal organoid culture in combination with nerves or fibroblasts: a method to characterize the gastrointestinal stem cell niche,” *Stem Cells International*, vol. 2016, Article ID 3710836, 16 pages, 2016.

[167] G. Noel, N. W. Baetz, J. F. Staab et al., “A primary human macrophage-enteroend co-culture model to investigate mucosal gut physiology and host-pathogen interactions,” *Scientific Reports*, vol. 7, no. 1, article 45270, 2017.

[168] J. In, J. Foulke-Abel, N. C. Zachos et al., “Enterohemorrhagic *Escherichia coli* reduce mucus and intermicrovillar bridges in human stem cell-derived colonoids,” *Cellular and Molecular Gastroenterology and Hepatology*, vol. 2, no. 1, pp. 48–62.e3, 2016.

[169] C. Moon, K. L. VanDussen, H. Miyoshi, and T. S. Steppenbeck, “Development of a primary mouse intestinal epithelial cell monolayer culture system to evaluate factors that modulate IgA transcytosis,” *Mucosal Immunology*, vol. 7, no. 4, pp. 818–828, 2014.

[170] S. S. Karve, S. Pradhan, D. V. Ward, and A. A. Weiss, “Intestinal organoids model human responses to infection by commensal and Shiga toxin producing *Escherichia coli*,” *PLoS One*, vol. 12, no. 6, article e0178966, 2017.

[171] J. L. Leslie, S. Huang, J. S. Opp et al., “Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function,” *Infection and Immunity*, vol. 83, no. 1, pp. 138–145, 2015.

[172] S. Ramani, S. E. Crawford, S. E. Blutt, and M. K. Estes, “Human organoid cultures: transformative new tools for human virus studies,” *Current Opinion in Virology*, vol. 29, pp. 79–86, 2018.

[173] A. Bein, W. Shin, S. Jalili-Firoozinezhad et al., “Microfluidic organ-on-a-chip models of human intestine,” *Cellular and Molecular Gastroenterology and Hepatology*, vol. 5, no. 4, pp. 659–668, 2018.

[174] C. J. Moran, C. Klein, A. M. Muise, and S. B. Snapper, “Very early-onset inflammatory bowel disease: gaining insight through focused discovery,” *Inflammatory Bowel Diseases*, vol. 21, no. 5, pp. 1166–1175, 2015.

[175] A. S. Lehle, H. F. Farin, B. Marquardt et al., “Intestinal inflammation and dysregulated immunity in patients with inherited caspase-8 deficiency,” *Gastroenterology*, vol. 156, no. 1, pp. 275–278, 2019.

[176] T. Schwert, R. V. Bryant, S. Pandey et al., “NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease,” *Mucosal Immunology*, vol. 11, no. 2, pp. 562–574, 2018.

[177] A. E. Bigorgne, H. F. Farin, R. Lemoine et al., “TTC7A mutations disrupt intestinal epithelial apicobasal polarity,” *The Journal of Clinical Investigation*, vol. 124, no. 1, pp. 328–337, 2014.

[178] K. Aden, F. Tran, G. Ito et al., “ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS-STING,” *The Journal of Experimental Medicine*, vol. 215, no. 11, pp. 2868–2886, 2018.

[179] M. Hohwieler, S. Renz, S. Liebau et al., “‘Miniguts’ from plucked human hair meet Crohn’s disease,” *Zeitschrift Fur Gastroenterologie*, vol. 54, no. 8, pp. 748–759, 2016.

[180] M. Noben, B. Verstockt, M. de Bruyn et al., “Epithelial organoid cultures from patients with ulcerative colitis and Crohn’s disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?”, *Gut*, vol. 66, no. 12, pp. 2193–2195, 2017.

[181] P. Xu, H. Becker, M. Elizalde, A. Mascele, and D. Jonkers, “Intestinal organoid culture model is a valuable system to study epithelial barrier function in IBD,” *Gut*, vol. 67, no. 10, pp. 1905–1906, 2018.

[182] R. Hasler, Z. Feng, L. Backdahl et al., “A functional methylene map of ulcerative colitis,” *Genome Research*, vol. 22, no. 11, pp. 2130–2137, 2012.

[183] J. Kraiczky, K. Nayak, A. Ross et al., “Assessing DNA methylation in the developing human intestinal epithelium: potential link to inflammatory bowel disease,” *Mucosal Immunology*, vol. 9, no. 3, pp. 647–658, 2016.

[184] A. Barnicle, C. Seoighe, J. M. Greally, A. Golden, and L. J. Egan, “Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis,” *Epigenetics*, vol. 12, no. 8, pp. 591–606, 2017.

[185] J. Cooke, H. Zhang, L. Greger et al., “Mucosal genome-wide methylation changes in inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 18, no. 11, pp. 2128–2137, 2012.

[186] T. Nakamura and M. Watanabe, “Beyond gene discovery in inflammatory bowel diseases di,” *Genes & Development*, vol. 28, no. 11, pp. 293–308, 2013.

[187] K. J. Howell, J. Kraiczky, K. M. Nayak et al., “DNA methylation and transcription patterns in intestinal epithelial cells from pediatric patients with inflammatory bowel diseases differentiate disease subtypes and associate with outcome,” *Gastroenterology*, vol. 154, no. 3, pp. 585–598, 2018.

[188] M. Fukuda, T. Mizutani, W. Mochizuki et al., “Small intestinal stem cell identity is maintained with functional Paneth cells in heterotopically grafted epithelium onto the colon,” *Genes & Development*, vol. 28, no. 16, pp. 1752–1757, 2014.

[189] T. Nakamura and M. Watanabe, “Intestinal stem cell transplantation,” *Journal of Gastroenterology*, vol. 52, no. 2, pp. 151–157, 2017.

[190] R. Okamoto and M. Watanabe, “Investigating cell therapy for inflammatory bowel disease,” *Expert Opinion on Biological Therapy*, vol. 16, no. 8, pp. 1015–1023, 2016.

[191] M. van de Watering, H. E. Francis, J. M. Francis et al., “Prospective derivation of a living organoid biobank of colorectal cancer patients,” *Cell*, vol. 161, no. 4, pp. 933–945, 2015.
[192] C. Cortina, G. Turon, D. Stork et al., “A genome editing approach to study cancer stem cells in human tumors,” EMBO Molecular Medicine, vol. 9, no. 7, pp. 869–879, 2017.

[193] J. Drost, R. H. van Jaarsveld, B. Ponsioen et al., “Sequential cancer mutations in cultured human intestinal stem cells,” Nature, vol. 521, no. 7550, pp. 43–47, 2015.

[194] B. C. E. Peck, A. T. Mah, W. A. Pitman, S. Ding, P. K. Lund, and P. Sethupathy, “Functional transcriptomics in diverse intestinal epithelial cell types reveals robust microRNA sensitivity in intestinal stem cells to microbial status,” The Journal of Biological Chemistry, vol. 292, no. 7, pp. 2586–2600, 2017.

[195] G. Schwank, B. K. Koo, V. Sasselli et al., “Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients,” Cell Stem Cell, vol. 13, no. 6, pp. 653–658, 2013.

[196] S. Hahn, M. O. Nam, J. H. Noh et al., “Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective,” Scientific Reports, vol. 7, no. 1, article 2435, 2017.